Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Being bearish but also bullish on Europe Inc

Wed, 07th Dec 2022 11:22

STOXX 600 down 0.5%

*

U.S. banks warn of recession

*

GSK rallies as Zantac lawsuits dismissed

*

U.S. stock futures slip

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

BEING BEARISH BUT ALSO BULLISH ON EUROPE INC (1116 GMT)

Jefferies goes straight to point to highlight how different each European country equity market is, which in turns means the dispersion of returns in the region is going to vary widely.

"One size doesn't fit all," says Sean Darby, one of the bank's global equity strategists.

Darby and team in fact are bullish on countries like France and the UK, modestly bullish on Germany, while at the same time, they're bearish on Poland and modestly so for Italy.

"European bourses are far from homogenous, so the dispersion of equity returns in 2023 will be quite wide," they say.

Bringing all together though, they see gains for the Euro STOXX betting that lead indicators will bottom out in the first half of 2023, followed by earnings revisions with a 3-month lag.

"There is room for the index to climb by ~12% as interest rates are likely to peak in 1Q23. This would leave the index trading on 480," they write.

EUROPEANS JUST LOVE GOOGLE (1039 GMT)

Growth stocks have been all the rage over the past few years, at least until late 2020, when it became apparent that the world economy was recovering and inflation was - at least at that point - ticking up at a comfortable pace. But once rates started rising and inflation began to rip higher, value stocks, which are more closely linked to the underlying economy, reemerged as a top pick. This year, European value stocks, which include the likes of energy, natural resources and autos, have gained 1.7%, compared with a drop of nearly 14% in growth stocks and an 11% fall in the broader STOXX.

In terms of what would-be European investors are interested in, the answer is clear, according to data from retail investing company CMC Markets. "Google" is the most searched-for growth stock in the region, topping the charts in 27 countries, with Meta's "Facebook" a close second, coming out on top in 20 countries. The number of searches varies depending on the population. Germany is the country with the highest number of searches a month and "Google" is the most popular, with 149,000 searches. The Netherlands is second, with 115,000 searches. Ukraine is the country with the most searches for "Facebook", with 107,000 searches a month, followed by the UK and France, with 87,000 and 86,000 searches, respectively.

"Google and Facebook are dominating as the most popular growth stocks across Europe. Both of these companies have a huge influence on the market, and the media, which is why many Europeans are looking to invest in them," Michael Hewson, chief market analyst at CMC Markets said.

FORZA ITALIA IN EARLY EUROPE (0915 GMT)

Italy may not have made it to the soccer World Cup, but Milan blue-chips are leading the way this morning, as European equities trade in a sea of red so far. The FTSE MIB is up 0.6%, by far the best performing index in the region, compared with a 0.1% loss in the broader STOXX 600 index, and well beyond Stockholm's 0.5% loss. Utility company ENEL is leading its sector higher and is up 1.5%, making it one of the biggest positive weights on the STOXX and lender UniCredit is up 1.8%.

But today belongs to the pharma and biotech sector, which is the standout gainer, up 1% thanks to a surge in shares of UK drugmaker GSK following a U.S. ruling that dismissed thousands of lawsuits claiming that over-the-counter heartburn medication Zantac causes cancer. The stock rose as much as 15% earlier on and, with a 10% gain, is on track for its largest one-day rise since 1998. French rival Sanofi, which is also part of the suit, is up 5.7%. All the drugmakers involved denied Zantac caused cancer.

HAT-TRICK (0755 GMT)

While European shares ended lower for the third straight session on Tuesday, spooked by recession worries, another hat-trick dominated the World Cup a few hours later.

Three goals by Portugal's 21-year-old Goncalo Ramos against Spain in his first World Cup sent his side through to the quarter-finals for the first time in 16 years. And a 3-0 shootout win by Morocco against former champions Spain meant that Morocco became the first Arab nation ever to qualify for the tournament's quarter-finals.

In the arena of European stocks, there seem to be little excitement for risky assets on Wednesday, with Asian equities trading rangebound after U.S. stocks again suffered losses as markets gradually factor in sharper interest rates hikes.

For the euro zone, commentary by officials is hinting at a peak in rates but anaemic growth and stubbornly high inflation are haunting investors.

ECB policymaker Constantinos Herodotou said on Tuesday that interest rates will go up again but are now "very near" their neutral level.

Markets will focus on industrial output data due from Germany, while euro zone third-quarter GDP and employment numbers, and UK house prices are among the other economic indicators for the day.

Euro zone government bond yields dropped for the first time in three days on Tuesday in the run-up to a raft of major central bank decisions next week.

A Reuters poll of market strategists expect the dollar to rebound against most currencies over the coming months, with the growing threat of recession in the U.S. and elsewhere keeping it firm in 2023 through safe-haven flows.

On Tuesday, top bankers from JPMorgan Chase & Co, Bank of America and Goldman Sachs warned of a recession next year, as inflation threatens consumer demand.

On the corporate front, Airbus gave up a numerical forecast for jet deliveries and a date for its key production goal but retained its financial targets as it limped towards the end of a year battered by disruptions in factories and supply chains.

And British Prime Minister Rishi Sunak's government said it would ease restrictions on building onshore wind farms, heading off a revolt by his party's lawmakers who had demanded they should be permitted with local support.

Key developments that could influence markets on Wednesday:

Economic data: Germany Oct industrial production, Euro zone Q3 GDP, employment (final), UK Nov Halifax house prices

Speakers: ECB's Philip Lane, Elizabeth McCaul and Fabio Panetta

More News
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.